2:41 Use of Electronic Health Records to Assess Risk for Lysosomal Storage Disease Pompe Disease Content Hub @DNADirectedDawn, of @EmoryGCTP, discusses severity #scoring systems as #screening for #lysosomalstoragediseases.
4:35 Safety and Efficacy of Asciminib in Third-Line Treatment for CML CML Content Hub @mjmauroMD, of @MSKCancerCenter, discusses #third-line treatment for #CML.
2:12 Well Tolerated in Preliminary Study: Pembrolizumab + TKIs in CML Patients With Persistent Detectible MRD CML Content Hub @Dr_AmerZeidan, of @Yale, discusses #safety of #pembrolizumab plus #TKIs in #CML.
2:00 Fractional Flow Reserve-Guided Percutaneous Coronary Intervention Did Not Meet Noninferiority Compared to Coronary Artery Bypass Surgery Cardiology Dr William Fearon of @StanfordUniversity discusses FAME3 trial outcomes.
3:12 Pancreatic Islet Transplantation: A New Cure for Type 1 Diabetes? Endocrinology Dr Philip O'Connell from Westmead Institute provides insights into the potential for curing type 1 diabetes with pancreatic islet cell transplants.
10:04 Long-Term Follow-Up of POUT Oncology Alison Birtle, MD, of @LancsHospitals, discusses updated results from the #POUT study, demonstrating increased #DFS with #chemo in #UTUC.
3:54 Immune Checkpoint Inhibitors in Upper and Lower Tract Urothelial Carcinoma Oncology @PGrivasMDPhD, from @SeattleCCA @UWDeptMedicine @fredhutch, discusses outcomes of #ICI therapy in #UTUC vs LTUC.
14:10 Data Updates From ASCO 2021 Oncology @amerseburger and @ERPlimackMD discuss data presented at #ASCO2021 on #urothelialcarcinoma.
1:49 Association Between Angiotensin Blockade and Response to PD-1/L1 Inhibition in Metastatic Urothelial Carcinoma Oncology @sonpavde, of @DanaFarber_GU, discusses the effects of #angiotensin blockade on #PD-1/L1 inhibition in #metastatic #urothelialcarcinoma.
5:48 Therapeutic Effects of WST11 Vascular-Targeted Photodynamic Therapy Urology @lucasmnnogueira, of @sloan_kettering, discusses the #safety and #efficacy of WST11 vascular-targeted #photodynamic therapy.
